Loading organizations...
Based in Planegg, Germany, CPTx is a biotechnology company that develops next-generation genetic medicines using an immune-silent single-stranded DNA platform for in vivo CAR-T and gene therapies. The organization leverages programmable DNA nanofabrication technology to create scalable nanostructures designed for antiviral solutions, biodefense initiatives, and broader oncology applications. Additionally, the enterprise operates a specialized contract development and manufacturing organization unit known as gxstrands, which produces high-quality, gene-length single-stranded DNA for various biopharma partners. The firm has raised nearly €55 million in total capital to date, which includes a recent $30 million financing round supported by institutional investors such as Blueyard Capital, SPRIND, Bayern Kapital, and the Marius Nacht Group. Building upon over fifteen years of academic research, CPTx was officially founded in 2021 as a spin-off from the Technical University of Munich by Hendrik Dietz and Christian Sigl.
CPTx has raised $29.0M across 1 funding round.
CPTx has raised $29.0M in total across 1 funding round.
CPTx has raised $29.0M in total across 1 funding round.
CPTx's investors include BlueYard Capital, Cyberstarts VC, Andrej Henkler.
CPTx has raised $29.0M across 1 funding round. Most recently, it raised $29.0M Series U in September 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2024 | $29M Series U | — | BlueYard Capital, Cyberstarts VC, Andrej Henkler | Announced |
CPTx is a biotechnology company specializing in the development of composite programmable therapeutics using immune-silent single-stranded DNA (ssDNA) technology. Its core product focus is on in vivo CAR-T cell therapies and programmable gene delivery platforms designed to treat complex diseases such as blood cancers, autoimmune disorders, and infectious diseases with precision and flexibility. CPTx aims to make advanced cell and gene therapies that are affordable, easily administered in clinical settings, and broadly accessible. The company is advancing its lead programs through preclinical stages, targeting an IND filing by 2027, and operates manufacturing facilities in Munich with a U.S. office in South San Francisco[1][2][4][6].
Founded in 2021 in Planegg, Germany, CPTx builds on over 15 years of pioneering work in programmable DNA nanofabrication led by Prof. Hendrik Dietz at the Technical University of Munich. The founding team includes experts in biotechnology and engineering who recognized the limitations of existing gene therapy vectors and sought to develop a redosable, tunable, and durable ssDNA + lipid nanoparticle (LNP) platform. Early traction includes successful preclinical development of an in vivo CAR-T therapy targeting CD19/CD20 for blood cancers and the establishment of proprietary manufacturing capabilities for advanced ssDNA constructs[1][3][4][6].
CPTx is riding the wave of next-generation genetic medicines that aim to overcome the limitations of current gene and cell therapies by enabling in vivo, programmable, and redosable treatments. The timing is critical as the biotech industry seeks safer, more flexible, and scalable therapeutic platforms beyond viral vectors and mRNA. Market forces such as increasing demand for precision oncology, autoimmune disease treatments, and pandemic preparedness align with CPTx’s antiviral and biodefense pipeline ambitions. By advancing ssDNA-based therapeutics, CPTx influences the broader ecosystem by pushing forward a new modality that could redefine gene therapy manufacturing and delivery[1][3][6].
Looking ahead, CPTx is positioned to become a leader in in vivo genetic medicines, with its IND filing expected in 2027 marking a key milestone. Trends shaping its journey include the growing acceptance of gene therapies, advances in AI-driven drug design, and the need for scalable, affordable treatments. CPTx’s influence may expand as it broadens its therapeutic targets beyond oncology to autoimmune and infectious diseases, potentially transforming how genetic medicines are developed and administered globally. Its proprietary manufacturing and platform technology could also enable strategic partnerships, accelerating innovation across the biotech sector[1][2][4][6].
